T-Cell Engagers: Vir Biotechnology Advances Healthcare Technology with Sanofi Licence Deal
Tuesday, 10 September 2024, 01:33
T-cell engagers are revolutionizing cancer therapies. Vir Biotechnology has successfully closed a licence deal with Sanofi, granting access to a suite of advanced clinical-stage T-cell engagers (TCEs) and the remarkable PRO-XTEN masking platform.
Through this strategic collaboration, both companies aim to optimize patient outcomes and broaden the scope of immunotherapy options.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.